EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Pierre Stéphan, Khaled Bouherrou iD, Yann Guillermin, Anne-Sophie Michallet, Yenkel Grinberg-Bleyer iD

Cells · 2024

DOI: 10.3390/cells13171458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Pierre Stéphan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, 69008 Lyon, France. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines, Immunophenotyping. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, ATIP/Avenir grant from INSERM/CNRS, INSERM/CNRS ATIP-Avenir.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), resistance can develop in CLL patients, and alternative therapeutic strategies are therefore required. Cancer immunotherapy has revolutionized cancer care and may be an attractive approach in this context. We speculated that characterizing the immune responses of CLL patients may highlight putative immunotherapeutic targets. Here, we used high-dimensional spectral flow cytometry to compare the distribution and phenotype of non-B-cell immune populations in the circulating blood of CLL patients treated with Ibrutinib displaying a complete response or secondary progression. Although no drastic changes were observed in the composition of their immune subsets, the Ibrutinib-resistant group showed increased cycling of CD8+ T cells, leading to their overabundance at the expense of dendritic cells. In addition, the expression of 11 different surface checkpoints was similar regardless of response status. Together, this suggests that CLL relapse upon Ibrutinib treatment may not lead to major alterations in the peripheral immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAdeninePiperidinesImmunophenotypingHumansMaleFemaleAgedMiddle AgedAged, 80 and overCD8-Positive T-LymphocytesBlood CellsPyrimidinesDrug Resistance, Neoplasm

Stichwörter der Autor:innen

chronic lymphocytic leukemiaimmunotherapyonco-immunologyspectral flow cytometry

Substanzen

ibrutinibAdeninePiperidinesPyrimidines

Autor:innen und Institutionen

  • Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, 69008 Lyon, France.
  • Hematology Department-Centre Léon Bérard, 69008 Lyon, France.

ORCID-Profile: Khaled Bouherrou, Yenkel Grinberg-Bleyer

Förderung

  • Agence Nationale de la Recherche
  • ATIP/Avenir grant from INSERM/CNRS
  • INSERM/CNRS ATIP-Avenir
  • Laboratory of Excellence (LabEx) Dev2Can
  • Fondation pour la Recherche Médicale

Zitieren

APA

Stéphan, P., Bouherrou, K., Guillermin, Y., Michallet, A. S., & Grinberg-Bleyer, Y. (2024). Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cells. https://doi.org/10.3390/cells13171458

Vancouver

Stéphan P, Bouherrou K, Guillermin Y, Michallet AS, Grinberg-Bleyer Y. Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cells. 2024. doi:10.3390/cells13171458

BibTeX
@article{Stphan2024,
  author = {Stéphan, Pierre and Bouherrou, Khaled and Guillermin, Yann and Michallet, Anne-Sophie and Grinberg-Bleyer, Yenkel},
  title = {Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13171458}
}
Kostenlos starten →